Fractyl Health (GUTS) Stock: Buy, Sell, or Hold?
GUTS - Fractyl Health, Inc. Common Stock
$1.08
-0.05 (-4.42%)
▼
5d:
-30.32%
30d:
+129.84%
90d:
+34.83%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
17d
Get Alerted When GUTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GUTS is down 30.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GUTS is down 30.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GUTS is currently trading at $1.08, which is considered fair relative to its 30-day fair value range of $0.15 to $3.59.
Technical Outlook: Technically, GUTS is in a downtrend. The price is currently testing key support at $1.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: GUTS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $38.67 (+3480.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GUTS is in a downtrend. The price is currently testing key support at $1.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: GUTS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $38.67 (+3480.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.15 -
$3.59
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- BULLISH: Trading 3480.2% below Wall St target ($38.67)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.15 -
$3.59
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.06
Resistance Level
$4.58
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.57
Wall Street Target
$38.67
(+3480.2%)
Revenue Growth (YoY)
-57.1%
Share & Embed Analysis
Last updated: October 23, 2026 9:33 PM ET
Data refreshes hourly during market hours. Next update: 10:33 PM
Data refreshes hourly during market hours. Next update: 10:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GUTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 72 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 43 HOLD |
